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relationship with the prognostic value of
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Mariana de Oliveira Diniz2, Hélène Roussel2,3, Eléonore De Guillebon7, Stéphane Oudard2,7, Stéphane Hans8,
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Abstract
Background: Our group has previously shown that EPHRIN-A1 and SCINDERIN expression by tumor cells rendered
them resistant to cytotoxic T lymphocyte-mediated lysis. Whereas the prognostic value of EPHRIN-A1 expression in
cancer has already been studied, the role of SCINDERIN presence remains to be established. In the present work,
we investigated the prognosis value of EPHRIN-A1 and SCINDERIN expression in head and neck carcinomas. In
addition, we monitored the HLA-class I expression by tumor cells and the presence of tumor-infiltrating CD8+ T cells
to evaluate a putative correlation between these factors and the survival prognosis by themselves or related to
EPHRIN-A1 and SCINDERIN expression.
Methods: Tumor tissue sections of 83 patients with head and neck cancer were assessed by immunohistochemistry
for the expression of EPHRIN-A1, SCINDERIN, HLA class I molecules and the presence of CD8+ T cells.
Results: No significant prognosis value could be attributed to these factors independently, despite a tendency of
association between EPHRIN-A1 and a worse clinical outcome. No prognostic value could be observed when CD8+ T cell
tumor infiltration was analyzed combined with EPHRIN-A1, SCINDERIN or HLA class I expression.
Conclusion: These results highlight that molecules involved in cancer cell resistance to cytotoxic T lymphocytes by
themselves are not a sufficient criteria for prognosis determination in cancer patients. Other intrinsic or tumor
microenvironmental features should be considered in prognostic evaluation.
Background
Head and neck cancer accounts for more than 550,000
cases annually worldwide and is the seventh most com-
mon cause of cancer-induced mortality [1,2]. Immune or
tumor related biomarkers such as serum cytokines, sol-
uble cytokine receptors, metalloproteinases, as well as
EGF-R expression and P53 mutations in tumor cells have
been identified as useful molecules for prognostic evalu-
ation [3-6]. However, because of their lack of specificity
or sensitivity and the need to reproduce these results in
multicentric studies, they have not been used in the
clinical practice so far.
T cell infiltration is emerging as novel type of cancer
biomarker based on the host immune response. Tumor-
infiltrating cytotoxic CD8+ T cells, in particular, are cap-
able of mediating directly the death of tumor cells via the
release of cytokines (IFNγ, TNF), cytotoxic factors (per-
forin, granzymes) or the engagement of ligand-receptor
interactions from the TNF family (TRAIL-TRAIL-R, FasL-
Fas, TNF-TNF-R) [7,8]. CD8+ T cells may also inhibit or
prevent cancer progression by favoring the intratumoral
recruitment of immune effectors including neutrophils,
macrophages and NK cells, promoting the amplification
of the in situ anti-tumor immune responses [9-11].
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A positive correlation between the patient survival
and the presence of a CD8+ T cell tumor infiltrate has
been reported [12-15]. These observations are further
supported by preclinical models that showed that the
CD8+ T cell concentration determines their cytolytic
function [16] and that tumor regression was mediated
by CD8+ T cells in mice [17]. On the other hand, high
densities of CD8+ T cells have also been associated with
tumor progression. In this regard, several studies on renal
cell carcinomas and hematological malignancies have
reported that high CD8+ T cell concentrations corre-
lated with bad prognosis [18-21].
Previously, our group has shown that CD8+ T infiltra-
tion in head and neck squamous cell carcinomas has no
prognostic value [22]. Several factors could be associated
with the lack of prognostic significance associated with
intratumoral CD8+ lymphocytes: absence or loss of HLA-
class I molecules on tumor cells, resistance of tumor
cells to immune attacks [23-28] and an anergic state of
CD8+ T cells mediated by the expression of negative
co-stimulatory molecules such as PD-1 [29,30].
EPH receptor tyrosine kinases and their EPHRIN li-
gands constitute a large cell communication system with
the ability of generating bidirectional signaling: forward
signals in EPH-receptor expressing cells and reverse sig-
nals in EPHRIN ligand-expressing cells [31]. These
signals can result in cytoskeleton reorganization, cell
adhesion or cell separation. Paradoxical observations
regarding expression of EPH receptors and EPHRINS
in cancer have been reported. Indeed, the up and down-
modulation of several EPH receptors and EPHRINS have
been described in different types of cancers compared to
their healthy tissues of origin [31]. The upregulation
of EPHRIN-A1 in hepatocellular carcinoma promoted
the proliferation and the expression of genes associ-
ated with proliferation and invasion [32]. The expression
of EPHRIN-A1 and its major receptor EPH-A2 were both
augmented and found to be significantly associated with
worse prognosis in oesophageal squamous cell carcinoma
where they correlated with shorter survival [33]. Greater
expression of EPHRIN-A1 and EPH-A2 were also found
in adenoid cystic carcinoma of the salivary gland and cor-
related with the tumor stage [34]. However, unbalanced
expression of EPHRIN-A1 and EPH-A2 was reported in
several cancers such as glioblastoma where in the absence
of EPHRIN-A1, EPH-A2 becomes a substrate for Akt,
promoting cell migration and invasion [35]. The onco-
genic properties of EPH and EPHRIN signaling have also
been analyzed. In this respect, EPH-dependent signals have
been reported to have tumor suppressive functions [36-38].
SCINDERIN is a member of the geslolin family of actin-
severing proteins which regulate the actin cytoskeleton by
severing pre-existing actin filaments, capping filaments
ends and nucleating actin assembly from monomers in a
calcium-dependent manner [39,40]. SCINDERIN has
been reported to play a role in exocytosis by mediating
disruption of F-actin cortical network, whereas the
other members of the gelsolin family, such as gelsolin,
contribute to cell motility. An anti-tumor role for
SCINDERIN has been described based on its capacity
to induce differentiation and apoptosis in megakaryo-
blastic leukemia cells that overexpress SCINDERIN [41].
In contrast, increased expression of SCINDERIN has
recently been related to resistance of bladder tumor
cells to cisplatin via inhibition of mitochondria-mediated
apoptosis [42].
We have previously reported that increased EPHRIN-A1
and SCINDERIN expression in tumor cells conferred resist-
ance to CD8+ T cell-mediated lysis by a mechanism linked
to actin cytoskeleton remodeling [26,43]. While previous
studies have shown increased expression of EPHRIN-A1 in
head and neck cancers [44], the expression of SCINDERIN
remains unestablished in these tumors. Our previous
observations in head and neck cancer indicated no prog-
nostic significance for CD8+ T cell infiltration [22,30].
Considering this, the present study was designed to ad-
dress whether the expression of proteins involved in the
resistance to cytotoxic CD8+ T cells such as EPHRIN-A1
and/or SCINDERIN or the downmodulation of HLA-class
I molecules, could explain the absence of clinical impact
of intratumoral CD8+ T cell infiltration in head and neck
cancer.
Methods
Ethic statement
This study was conducted in accordance with the french
laws and was approved by the local ethic committee
(Comité de Protection des Personnes "Ile de France II",
n°ID RCB 2007-A01128-45). Patients provided their writ-
ten informed consent (approved by the ethic committee)
to participate in this study.
Patients
83 patients with untreated and histologically diagnosed
head and neck squamous cell carcinoma were enrolled for
EPHRIN-A1 and SCINDERIN expression analysis from
January 2004 to December 2011. Each patient disease
stage was classified according to the 7th edition of the
International Union Against Cancer/American Joint
Committee on Cancer system for head and neck cancer.
Treatments consisted of chemo-radiotherapy without
surgery (organ preservation) or surgery combined or
not with chemo-radiotherapy. Patients were matched for
various parameters (gender, primary tumor site, tumor
staging, lymph node involvement, presence of metastasis,
HPV status and treatment modalities; Table 1).
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Immunohistochemical staining
Frozen sections (4 μm thick) of tumors were fixed in
formol 4%, transferred in Citrate Buffer pH = 6 (MM
France, T/T0050) in decloaking chamber for 20 min,
blocked with blocking buffer (Dako, Glostrup, Denmark;
X0909) and stained either with anti-SCINDERIN (Sigma-
aldrich, St. Louis, MO, USA; 2.75 μg/ml), anti-EphrinA1
(Santa-Cruz biotechnologies, Santa Cruz, CA, USA;
0.7 μg/ml) or anti-HLA class I (anti-β2 microglobuline
antibody produced in our laboratory, 0.05 μg/ml) antibodies.
Tissue sections were further treated with peroxydase-
conjugated secondary antibodies (DAKO, Glostrup, Denmark;
EnVision K4003) and counterstained with Mayer’s hema-
lum for better nuclei visualisation.
HPV status (Table 1) was estimated by immunochem-
istry using prediluted anti- p16 INK4a CINtec® antibody
(Roche) for 73 patients out of 83. Samples from the
remaining 10 patients were not available due to the small
size of the biopsies. The staining was performed using
the BenchMark Clyde ULTRAVentana Roche apparatus.
The specificity of anti-EPHRIN-A1 and anti-SCINDERIN
antibodies was assessed by Western-blot on the tumor cells
(IGR-Heu cells issued from a non-small cell lung carcinoma
biopsy) transfected with empty vector or plasmids encoding
either EPHRIN-A1 (Figure 1A) or SCINDERIN (Figure 1B).
Transfections were performed using Lipofectamine® 2000
reagent (Invitrogen).
Immunofluorescence staining
Tissue samples obtained before any treatment at initial
endoscopy or surgery were immediately frozen and stored
at −80°C. Frozen specimens were sectioned at 4 μm with
a cryostat, placed on slides, air dried and fixed for
10 min. Before incubation with anti-CD8 (Abcam; ab4055;
Table 1 Patient characteristics
Category Subcategory Results
Sex Male 75
Female 8
Age <50 y 7
50-65 y 55
≥66 y 21
Primary tumor site Oral cavity 10
Oropharynx 31
Hypopharynx 16
Larynx 26
Tumor (T) staging T1 6
T2 19
T3 26
T4 32
Lymph node involvment N0 22
N1 11
N2 41
N3 8
N4 1
Metastasis M0 76
M1 7
Treatment Surgery 8
Chemoradiotherapy 35
Surgery + chemoradiotherapy 39
None 1
HPV status Positive 14
Negative 59
Not determined 10
EPHRIN-A1
ACTIN
A
SCINDERIN
ACTIN
B
Figure 1 Western-blot analysis of anti-EPHRIN-A1 and
anti-SCINDERIN antibody specificity. Non-small cell lung
carcinoma cells (IGR-Heu) were transfected with empty vector or
plasmids encoding either EPHRIN-A1 or SCINDERIN. Antibody
specificity was further assessed by western-blot analysis of protein
cell extracts.
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1 μg/ml) antibody, the slides were treated with avidin/
biotin blocker (Vector Laboratories, Burlingame, CA)
and Fc receptor was blocked with human serum (5%).
Isotype-matched antibodies were used as negative con-
trols. Fluorescent images of mounted sections were ana-
lyzed with an epifluorescent microscope (DMR, Leica
Microsystems, Wetzlar, Germany).
Scoring procedure
A semi-quantitative grading system was used to quan-
tify the tumor infiltrating CD8+ T cell subpopulations,
EPHRIN-A1 and HLA-class I expression by tumor cells.
The staining was scored as 0 (less than 10% positive cells),
1 (10-20% positive cells), 2 (21-50% positive cells), 3 (more
than 50% positive cells) based on reference staining slides
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Figure 2 Immunochemical and immunofluorescent staining with the anti-W6-32, SCINDERIN, EPHRIN-A1 and CD8 antibodies in squamous
cell carcinoma. Tissue sections derived from biopsies of head and neck cancers were stained with antibodies to human HLA class I, SCINDERIN,
EPHRIN-A1 and CD8. A (positive), B (negative -arrows) HLA class I stainings; C (positive), D (negative) SCINDERIN stainings; E (positive), F (negative)
EPHRIN-A1 stainings; G (low), H (high) CD8+ T cell infiltrations.
Hasmim et al. BMC Cancer 2013, 13:592 Page 4 of 12
http://www.biomedcentral.com/1471-2407/13/592
using a high magnification (x400). As previously reported,
the cut-off for high and low expression group was arbi-
trarily set up as > or ≤ 20% positively stained cells respect-
ively [30]. For SCINDERIN expression, only the presence
or the absence of its expression by tumor cells was
recorded. Examples of staining are shown in Figure 2.
Level of expression for each marker is summarized in
Table 2.
The mean of positively stained cells in at least five
fields using a 40x objective was selected for each sample.
Two authors (C.B. and E.T.) blinded for clinical data,
independently scored the slides.
Statistical analyses
The relationship between the different staining was
analyzed by the m2 test or the Fisher’s exact test as
necessary. Survival variables were estimated using the
Kaplan-Meier method and compared by the log-rank
test. Multivariate analysis using the Cox proportional
hazard model determined the influence of each vari-
able, when adjusted to others, on locoregional control
(relapse free survival) and overall survival. The level of
significance was set at P V 0.05. Overall survival was
defined as the time from initial diagnosis until death
or until last follow-up (right censored data). Overall
survival took all deaths into account. Locoregional control
was calculated from the end of treatment and was defined
as the absence of disease or either persistent or recurrent
disease at the primary site or in the cervical lymph nodes.
Patients with persistent disease at the end of treatment
were considered to have experienced failure at time zero.
Patients with no signs of relapse were censored at the
time of last follow-up or death.
Results
Prognosis value of treatments in head and neck cancers
Patients who were treated by surgery alone or combined
with chemo-radiotherapy had a better overall survival
than patients treated by chemo-radiotherapy alone, as
shown in Figure 3. In this work, we did not focus on
the prognostic value of the clinical parameters (sex,
age, primary tumor site, TNM staging) listed in Table 1
as it was not the aim of the current study. We and
others have already addressed their prognostic value in
head and neck cancers and found that the TNM classi-
fication was correlated with overall survival, whereas
sex, age and primary tumor site had no impact on the
clinical outcome [4,45].
CD8+ T cell infiltration was not associated with an
improved prognosis in head and neck cancer patients
In our series of 83 patients, those with high infiltration
of CD8+ T cells (n = 39), defined by more than 20% of
infiltrating cells (see Methods), had a median overall
survival time of 59 months. Patients with low infiltra-
tion of CD8+ T cells (n = 44) presented a median over-
all survival time of 24 months (Figure 4A), however
this difference did not reach statistical significance
(HR: 0.85. 95% CI, 0.48-1.5; p = 0.57). In accordance
with these results, the difference in CD8+ T cell infiltra-
tion in head and neck cancer patients did not confer
significant advantage on locoregional control (relapse
free survival) (p = 0.12) (Figure 4B). Another cut-off
selected to discriminate low or high CD8+ T cell
Table 2 Number of patient for each marker expression
0 1 2 3
CD8 6 38 21 18
HLA-class I 32 38 12 1
EPHRIN-A1 33 12 6 32
SCINDERIN 74 9
Except for SCINDERIN, a marker expression of 0 to 1 is considered as low and
of 2 to 3 as high.
(months)
P = 0.0006
Surgery
Chemo-radiotherapy
Surgery + chemo-
radiotherapy
Figure 3 Overall survival in head and neck carcinoma treated by surgery, chemo-radiotherapy or surgery combined with chemo-radiotherapy.
Overall survival of 83 head and neck carcinoma patients based on the type of treatments.
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infiltration did not change the absence of correlation
between CD8+ T cell infiltration and prognosis (data
not shown).
We next attempted to investigate some tumoral fea-
tures known to impact CD8+ T cell activity.
The non prognostic value associated with intratumoral
CD8+ T cells does not correlate with a decrease in tumor
MHC class I molecules
Since the anti-tumor activity of CD8+ T cells requires
the expression of HLA-class I molecules by tumor cells,
we assessed its expression in head and neck cancers.
Using various cut-off we did not find any correlation be-
tween the presence of HLA-Class I molecules detected
by an anti-β2 microglobulin mAb and the CD8+ T cell
infiltration (data not shown). We found that 32 out of
83 patients did not express HLA-class I molecules and
38 patients express HLA class I molecules in less than
20% of cells. These two groups of patients were gathered
in the low HLA class I expressing group. Thirteen tu-
mors from head and neck cancer patients expressed
high levels of HLA-class I molecules. Surprisingly, pa-
tients whose tumors expressed low levels of HLA-class I
molecules exhibited a better prognosis as assessed by
median overall survival (31 months), than patients ex-
pressing high levels of HLA-class I molecules in their
tumors (15 months) (Figure 5A). However, this differ-
ence was not statistically significant (HR: 1.56. 95%
CI 0.67-3.6; p = 0.2).
When we combined the analyses of low and high
intratumoral CD8+ T cell infiltration and the low and
high HLA-class I expression groups, it did not improve
the overall survival (Figure 5B) (p = 0.7). Unexpectedly,
patients with high CD8+ T cell infiltration and low
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Figure 4 No prognostic value of intratumoral CD8+ T cells in head and neck cancer. Tissue sections derived from biopsies of head and
neck cancers were stained with the anti-CD8 antibody by simple immunofluorescence analysis. For overall survival analysis (A) and disease free
survival analysis (B), high and low levels of these populations were defined as low (≤ 20% positively stained tumor cells) versus high (> 20%
positively stained cells).
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HLA-class I expression presented a poor outcome,
as the overall survival analysis of this group was
15 months compared to the 25 months overall sur-
vival for the group of patients with low CD8+ T cell
infiltration and low expression of HLA-class I molecules
(Figure 5B).
Expression of EPHRIN-A1 by tumor cells tends to be
associated with worse survival independently of CD8+ T
cell infiltration
Since we previously demonstrated that the expression of
EPHRIN-A1 and SCINDERIN by tumor cells resulted in
their resistance to the lysis by anti-tumoral CD8+ T cells
[26], we analyzed the expression of EPHRIN-A1 and
SCINDERIN in head and neck cancer patients and
combined the study of these cytoskeletal biomarkers
with CD8+ T cell infiltration.
Using the same cut-off (> 20% positive cells) to dis-
criminate high (n = 38) and low (n = 45) EPHRIN-A1 ex-
pression, we showed that head and neck cancer patients
with high EPHRIN-A1 expression have a reduced median
survival (20 months) compared to patients with low
expression of EPHRIN-A1 (70 months). However, this
tendency did not reach statistical significance (HR: 1.6.
95% CI 0.9 to 2.8. p = 0.09) (Figure 6A). When the
CD8+ high and low groups were sub-classified depending
on the expression of EPHRIN-A1, we found, as expected,
that patients with high CD8+ T cell infiltration combined
to those with low EPHRIN-A1 expression have a better
median overall survival (82 months), than patients with
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Figure 5 Expression of HLA class I by tumor cells is not associated with prognosis and does not improve the prognostic value of
intratumoral CD8+T cells. A) Tissue sections derived from biopsies of head and neck cancers were stained with the anti-HLA class I antibody by
simple immunochemical analysis. For overall survival analysis, high and low levels of these populations were defined as low (0, 1) versus high (2, 3).
B) CD8 and HLA-class I stainings were measured in biopsies derived from head and neck cancer patients. The combination of these two stainings
and the overall survival are represented. For overall survival analysis, the high and low groups for each population were combined.
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low CD8+ T cell infiltration and high EPHRIN-A1 expres-
sion (20 months), but this difference did not reach stat-
istical significance (p = 0.33) (Figure 6B).
SCINDERIN expression does not correlate with prognosis
in head and neck cancer and does not improve the
prognostic value of the CD8 biomarker after its
combination
SCINDERIN is weakly expressed by head and neck tumors,
as only 9 out of 83 patients expressed this biomarker.
Patients expressing SCINDERIN have no survival
advantage compared to patients with no expression of
this cytoskeletal biomarker (p = 0.8) (Figure 7A).
Due to the low number of patients expressing SCIN-
DERIN, we combined the EPHRIN-A1 and SCINDERIN
expression to address whether the presence of either
SCINDERIN or EPHRIN-A1, possible surrogate markers
of resistance of tumor cells to lysis mediated by CD8+ T
cells, could influence the impact of CD8+ T cell on the
clinical outcome of patients. Data shown in Figure 7B
indicate that patients with high CD8+ T cell infiltration
and lacking EPHRIN-A1 and SCINDERIN did not
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Figure 6 Expression of EPHRIN-A1 tends to be associated with worse survival but does not explain the absence of prognostic value of
intratumoral CD8+T cells. Intratumoral CD8+T cells in the absence of EPHRIN-A1 are not associated with a better prognosis. (A) Tissues
derived from biopsies of head and neck cancers were stained with anti-EPHRIN-A1 antibody by simple immunochemical analysis. For overall
survival analysis, high and low levels of this population were defined as low (≤ 20% of positive staining cells) versus high (> 20% positive staining cells).
(B) CD8 and EPHRIN-A1 stainings were measured in biopsies derived from head and neck cancer patients. The combination of these two stainings
and the overall survival are represented. For overall survival analysis, the high and low group for each population were combined.
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exhibit a better prognosis than the other groups of
patients (Figure 7B) (p = 0.6).
When we combined all the possible mechanisms of tumor
resistance to CD8+ T cells (HLA class I loss, EPHRIN-A1
and SCINDERIN expression), patients with high CD8+ T
cells infiltration expressing HLA-class I molecules on
tumor cells and with low tumor expression of EPHRIN-
A1 and SCINDERIN did not exhibit a better prognosis
than the other groups of patients (data not shown).
Discussion
Consistent with previous data reported by our group
[22,30], we found in the present study that the levels of
intratumoral CD8+ Tcell infiltration did not correlate with
overall survival or locoregional control in head and neck
cancer patients. This is in agreement with other reports
indicating an absence of significant statistical correlation
between intratumoral CD8+ or CD3+ T cell infiltration
and the clinical outcome in head and neck cancer patients
[46-48]. Since partial or complete loss of HLA-class I
expression have been reported in head and neck tumors
[49,50], we examined whether this could explain the
weak impact of intratumoral CD8+ T cell infiltration on
the clinical outcome. We found that head and neck can-
cer patients had a complete loss or a weak expression
of HLA-class I molecules in 38.5% and 45.7% of the
cases, respectively. Although it did not reach statistical
significance, patients with high CD8+ T cell infiltration
combined with low HLA class I expression exhibited a
better prognosis than patients in which CD8+ T cell
presence is associated with high HLA class I expression.
This paradoxical result parallels the negative correlation
between HLA expression and good clinical outcome for
HPV-positive head and neck cancer, recently reported
by Nasman’s group [51]. Patients with high CD8+ T cell
infiltration and low HLA-class I expression may have
experienced HLA class I molecules immunoediting, as a
consequence of immune selection after the induction of
an anti-tumor immune response. The absence of HLA
class I molecules may represent a surrogate marker of
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Figure 7 SCINDERIN expression did not correlate with prognosis in head and neck cancer and did not explain the absence of
prognostic value of intratumoral CD8+T cells. (A) Tissues derived from biopsies of head and neck cancers were stained with the anti-SCINDERIN
antibody by simple immunochemical analysis. For overall survival analysis, the low and high groups were defined depending on the absence or
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patients. The combination of these two stainings and the overall survival are represented. For overall survival analysis, the high and low group for
each population were combined.
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an anti-tumor immune response and could therefore be
associated with a good clinical outcome. Furthermore,
low HLA class I expression could also be related to a
natural killer cell immune response directed against the
tumor cells.
Our group showed that SCINDERIN and EPHRIN-A1
are directly responsible for conferring resistance to tumor
cells from CD8+ T cell attack [26]. Although a tendency
between high expression of EPHRIN-A1 and overall sur-
vival was observed (p = 0.09), the expression of this cyto-
skeletal biomarker did not significantly correlate with the
clinical outcome in patients with head and neck cancers
(Figure 5 and Figure 6). A correlation between EPHRIN-A1
expression and the overall survival in head and neck squa-
mous cell carcinomas has been previously reported [44].
The present study indicated that patients with high
CD8+ T cell infiltration have a better prognosis, once
associated with low EPHRIN-A1 expression, but this
correlation did not reach statistical significance. The
stratification of patients with CD8+T cell infiltration related
to SCINDERIN expression or the combined EPHRIN-A1,
SCINDERIN and HLA-class I expression did not im-
prove the prognostic value of CD8+ T cell infiltration.
Different studies reported an association between intra-
tumoral CD8+ T cell infiltration and a good prognosis in
subgroups of head and neck cancer patients defined by
the presence of HPV, their low clinical aggressiveness or
their location [52-54]. This may explain some discrepan-
cies reported in the literature upon the prognostic value
of intratumoral CD8+ T cells in head and neck cancer
patients [55]. However, in previous studies we could not
demonstrate a relationship between infiltrating CD8+ T
cells and the clinical outcome, independently of the
HPV status of the patients [30]. Other groups claim that
the presence of intratumoral CD8+ T cell is more pre-
dictive of the clinical outcome, when considering the
CD4/CD8 [46] or the CD8/CCR4+regulatory T cells
(Treg) ratios [56,57]. The location of the lymphocytic
infiltrates within the tumor (tumor nest or stroma) could
also explain the discrepant significance of the intratu-
moral CD8+ T cell presence [56]. In the present work,
we accessed the total number of CD8+ T cells regardless
of their tumor location, due to the practice of non-
automated counting and impossibility of accurate dis-
crimination of the CD8+ T cells in the various locations.
Conclusions
We investigated the putative prognosis value of two
molecules involved in tumor cell resistance to CD8+ T
cell-mediated lysis, EPHRIN-A1 and SCINDERIN. Over-
all, our results show that molecules mediating tumor
resistance to CD8+ T cells could not be used as reliable
markers for prognostic evaluation in head and neck
cancer patients. Moreover, in contrast to other tumor
types, intratumoral infiltration of CD8+ T cells was not
a compatible clinical biomarker in head and neck tumors.
The prognosis value of these different factors could be
clarified by additional analyses of tumor cell phenotype,
the profile of their microenvironment or specific features
of the tumor cells.
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